{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:33:22Z","timestamp":1779114802293,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tuberous sclerosis (TSC) is a hamartoma syndrome in which renal and lung tumors cause the greatest morbidity. Loss of either TSC1 or TSC2 in TSC hamartomas leads to activation of mTORC1 and suppression of AKT. Recent studies indicate that inhibition of mTORC1 with RAD001 (everolimus) leads to rebound activation of AKT, which could protect tumors from drug-induced cell death. Here we examine the potential benefit of inhibition of both mTOR and AKT signaling in a mouse model of TSC, using a dual pan class I PI3K\/mTOR catalytic small molecule inhibitor NVP-BEZ235.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Using ENU to enhance <jats:italic>Tsc2<\/jats:italic>\n              <jats:sup>+-<\/jats:sup> kidney tumor development, both RAD001 (10 mg\/kg PO 5 d\/week) and NVP-BEZ235 (45 mg\/kg PO QD) had equivalent effects in suppressing tumor development during a 4 week treatment period, with a 99% reduction in tumor cell mass. Marked reduction in activation of mTORC1, induction of cell cycle arrest, and absence of apoptotic cell death was seen in mice treated with either drug. However, when either was discontinued, there was prompt recovery of tumor growth, with extensive proliferation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Both mTORC1 blockade alone and combined PI3K-mTOR blockade lead to suppression of tumor development but not tumor elimination in this TSC model.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1476-4598-8-38","type":"journal-article","created":{"date-parts":[[2009,6,16]],"date-time":"2009-06-16T06:14:44Z","timestamp":1245132884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis"],"prefix":"10.1186","volume":"8","author":[{"given":"Kristen","family":"Pollizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Malinowska-Kolodziej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Stumm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,6,15]]},"reference":[{"key":"423_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. N Engl J Med. 2006, 355: 1345-56. 10.1056\/NEJMra055323.","journal-title":"N Engl J Med"},{"key":"423_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/j.1523-1755.2004.00838.x","volume":"66","author":"JJ Bissler","year":"2004","unstructured":"Bissler JJ, Kingswood JC: Renal angiomyolipomata. Kidney Int. 2004, 66: 924-34. 10.1111\/j.1523-1755.2004.00838.x.","journal-title":"Kidney Int"},{"key":"423_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1378\/chest.07-0898","volume":"133","author":"FX McCormack","year":"2008","unstructured":"McCormack FX: Lymphangioleiomyomatosis: a clinical update. Chest. 2008, 133: 507-16. 10.1378\/chest.07-0898.","journal-title":"Chest"},{"key":"423_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI7319","volume":"104","author":"H Onda","year":"1999","unstructured":"Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ: Tsc2(+\/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest. 1999, 104: 687-95. 10.1172\/JCI7319.","journal-title":"J Clin Invest"},{"key":"423_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/hmg\/11.5.525","volume":"11","author":"DJ Kwiatkowski","year":"2002","unstructured":"Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, Onda H: A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet. 2002, 11: 525-34. 10.1093\/hmg\/11.5.525.","journal-title":"Hum Mol Genet"},{"key":"423_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1494","volume":"37","author":"K Inoki","year":"2005","unstructured":"Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005, 37: 19-24. 10.1038\/ng1494.","journal-title":"Nat Genet"},{"key":"423_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 2007, 12: 9-22. 10.1016\/j.ccr.2007.05.008.","journal-title":"Cancer Cell"},{"key":"423_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1203\/01.PDR.0000147727.78571.07","volume":"57","author":"H Kenerson","year":"2005","unstructured":"Kenerson H, Dundon TA, Yeung RS: Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res. 2005, 57: 67-75. 10.1203\/01.PDR.0000147727.78571.07.","journal-title":"Pediatr Res"},{"key":"423_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/gcc.20118","volume":"42","author":"L Lee","year":"2005","unstructured":"Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL: Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer. 2005, 42: 213-27. 10.1002\/gcc.20118.","journal-title":"Genes Chromosomes Cancer"},{"key":"423_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1083\/jcb.200403069","volume":"166","author":"LS Harrington","year":"2004","unstructured":"Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004, 166: 213-23. 10.1083\/jcb.200403069.","journal-title":"J Cell Biol"},{"key":"423_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1172\/JCI200317222","volume":"112","author":"H Zhang","year":"2003","unstructured":"Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ: Loss of Tsc1\/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest. 2003, 112: 1223-33.","journal-title":"J Clin Invest"},{"key":"423_CR12","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66: 1500-8. 10.1158\/0008-5472.CAN-05-2925.","journal-title":"Cancer Res"},{"key":"423_CR13","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","volume":"7","author":"S Maira","year":"2008","unstructured":"Maira S, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Ch\u00e8ne P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garc\u00eda-Echeverr\u00eda C: Identification and characterization of NVP-BEZ235, a new orally available dual PI3K\/mTOR inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008, 7: 1851-63. 10.1158\/1535-7163.MCT-08-0017.","journal-title":"Mol Cancer Ther"},{"key":"423_CR14","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/0008-5472.CAN-04-3840","volume":"65","author":"N El-Hashemite","year":"2005","unstructured":"El-Hashemite N, Walker V, Kwiatkowski DJ: Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res. 2005, 65: 2474-81. 10.1158\/0008-5472.CAN-04-3840.","journal-title":"Cancer Res"},{"key":"423_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","volume":"8","author":"M Breuleux","year":"2009","unstructured":"Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA: Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K\/mTOR inhibition. Mol Cancer Ther. 2009, 8: 742-53. 10.1158\/1535-7163.MCT-08-0668.","journal-title":"Mol Cancer Ther"},{"key":"423_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008, 358: 140-51. 10.1056\/NEJMoa063564.","journal-title":"N Engl J Med"},{"key":"423_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1056\/NEJMc072500","volume":"358","author":"DM Davies","year":"2008","unstructured":"Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR: Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med. 2008, 358: 200-3. 10.1056\/NEJMc072500.","journal-title":"N Engl J Med"},{"key":"423_CR18","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1101\/gad.1314605","volume":"19","author":"BD Manning","year":"2005","unstructured":"Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC: Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 2005, 19: 1773-8. 10.1101\/gad.1314605.","journal-title":"Genes Dev"},{"key":"423_CR19","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science. 2005, 307: 1098-101. 10.1126\/science.1106148.","journal-title":"Science"},{"key":"423_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol Cell. 2006, 22: 159-68. 10.1016\/j.molcel.2006.03.029.","journal-title":"Mol Cell"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-8-38.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:33:19Z","timestamp":1630452799000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-8-38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,15]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["423"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-8-38","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,15]]},"assertion":[{"value":"23 January 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"38"}}